Baker Bros. Advisors Lp Buys Madrigal Pharmaceuticals Inc, Allakos Inc, Tricida Inc, Sells Exact Sciences Corp, Audentes Therapeutics Inc, uniQure NV

• New Purchases: ADAP, BDSI, HZNP, ALEC, IMMU, TARA, CABA, NERV, GBT, NGM, KRTX, XLRN, MRKR, DNLI, ARYA, DRNA, APLT, OVID,
• Added Positions: ALXN, ACAD, KOD, MDGL, ALLK, TCDA, CERS, APLS, INSM, PRNB, MRTX, ALKS, ISEE, CCXI, AXSM, PTGX, RETA, ANAB, ALBO, MTNB, ARAV,
• Reduced Positions: EXAS, QURE, ADPT, URGN, KRYS, ABEO, NBIX, CPRX, EVFM, CTMX, GTHX, MTEM, BLCM, MNLO, HARP, IDYA,
• Sold Out: BOLD, NXTC, GX1N, YMAB, TRIL, SBPH, DVAX,

For the details of BAKER BROS. ADVISORS LP's stock buys and sells, go to https://www.gurufocus.com/guru/baker+bros.+advisors+lp/current-portfolio/portfolio

1. Seattle Genetics Inc (SGEN) - 50,060,240 shares, 36.31% of the total portfolio. Shares added by 0.01%
2. Incyte Corp (INCY) - 31,978,785 shares, 14.72% of the total portfolio. Shares added by 0.01%
3. ACADIA Pharmaceuticals Inc (ACAD) - 41,904,586 shares, 11.13% of the total portfolio. Shares added by 2.57%
4. BeiGene Ltd (BGNE) - 11,777,285 shares, 9.12% of the total portfolio.
5. Alexion Pharmaceuticals Inc (ALXN) - 8,760,794 shares, 4.95% of the total portfolio. Shares added by 6.09%

Baker Bros. Advisors Lp initiated holding in Adaptimmune Therapeutics PLC. The purchase prices were between $1.2 and $4.52, with an estimated average price of $3.32. The stock is now traded at around $4.86. The impact to a portfolio due to this purchase was 0.06%. The holding were 3,690,307 shares as of .

Baker Bros. Advisors Lp initiated holding in BioDelivery Sciences International Inc. The purchase prices were between $3.06 and $6.32, with an estimated average price of $4.96. The stock is now traded at around $4.79. The impact to a portfolio due to this purchase was 0.04%. The holding were 1,638,334 shares as of .

Baker Bros. Advisors Lp initiated holding in Alector Inc. The purchase prices were between $16.25 and $35.28, with an estimated average price of $25.37. The stock is now traded at around $31.47. The impact to a portfolio due to this purchase was 0.04%. The holding were 280,000 shares as of .

Baker Bros. Advisors Lp initiated holding in Horizon Therapeutics PLC. The purchase prices were between $24.87 and $38.56, with an estimated average price of $33.97. The stock is now traded at around $48.75. The impact to a portfolio due to this purchase was 0.04%. The holding were 200,000 shares as of .

Baker Bros. Advisors Lp initiated holding in Minerva Neurosciences Inc. The purchase prices were between $4.57 and $9.23, with an estimated average price of $7.57. The stock is now traded at around $13.47. The impact to a portfolio due to this purchase was 0.03%. The holding were 688,531 shares as of .

Baker Bros. Advisors Lp initiated holding in Immunomedics Inc. The purchase prices were between $9.48 and $21.16, with an estimated average price of $16.95. The stock is now traded at around $33.30. The impact to a portfolio due to this purchase was 0.03%. The holding were 310,000 shares as of .

Baker Bros. Advisors Lp added to a holding in Madrigal Pharmaceuticals Inc by 28.22%. The purchase prices were between $66.76 and $93.49, with an estimated average price of $83.57. The stock is now traded at around $116.42. The impact to a portfolio due to this purchase was 0.14%. The holding were 1,499,212 shares as of .

Baker Bros. Advisors Lp added to a holding in Allakos Inc by 116.51%. The purchase prices were between $44.49 and $95.36, with an estimated average price of $68.99. The stock is now traded at around $69.42. The impact to a portfolio due to this purchase was 0.11%. The holding were 735,469 shares as of .

Baker Bros. Advisors Lp added to a holding in Tricida Inc by 35.34%. The purchase prices were between $18.43 and $38.04, with an estimated average price of $32.3. The stock is now traded at around $27.19. The impact to a portfolio due to this purchase was 0.1%. The holding were 2,666,015 shares as of .

Baker Bros. Advisors Lp added to a holding in Cerus Corp by 27.57%. The purchase prices were between $2.87 and $5.49, with an estimated average price of $4.52. The stock is now traded at around $6.08. The impact to a portfolio due to this purchase was 0.09%. The holding were 13,713,195 shares as of .

Baker Bros. Advisors Lp added to a holding in Apellis Pharmaceuticals Inc by 80.40%. The purchase prices were between $17.91 and $44.33, with an estimated average price of $35.6. The stock is now traded at around $34.06. The impact to a portfolio due to this purchase was 0.07%. The holding were 896,551 shares as of .

Baker Bros. Advisors Lp added to a holding in Insmed Inc by 23.72%. The purchase prices were between $13.63 and $33.98, with an estimated average price of $23.78. The stock is now traded at around $24.95. The impact to a portfolio due to this purchase was 0.06%. The holding were 3,025,384 shares as of .

Baker Bros. Advisors Lp sold out a holding in Audentes Therapeutics Inc. The sale prices were between $59.83 and $60, with an estimated average price of $59.94.

Baker Bros. Advisors Lp sold out a holding in NextCure Inc. The sale prices were between $32.32 and $58.37, with an estimated average price of $44.81.

Baker Bros. Advisors Lp sold out a holding in Y-mAbs Therapeutics Inc. The sale prices were between $14.39 and $35.8, with an estimated average price of $29.19.

Baker Bros. Advisors Lp sold out a holding in Marker Therapeutics Inc. The sale prices were between $1.48 and $2.93, with an estimated average price of $2.32.

Baker Bros. Advisors Lp sold out a holding in Spring Bank Pharmaceuticals Inc. The sale prices were between $0.8 and $2.04, with an estimated average price of $1.3.

Baker Bros. Advisors Lp sold out a holding in Trillium Therapeutics Inc. The sale prices were between $1.03 and $7.22, with an estimated average price of $3.72.

Baker Bros. Advisors Lp reduced to a holding in Exact Sciences Corp by 28.6%. The sale prices were between $37.9 and $104.44, with an estimated average price of $81.73. The stock is now traded at around $83.89. The impact to a portfolio due to this sale was -0.37%. Baker Bros. Advisors Lp still held 1,846,139 shares as of .

Baker Bros. Advisors Lp reduced to a holding in uniQure NV by 31.03%. The sale prices were between $40.01 and $73.97, with an estimated average price of $57.92. The stock is now traded at around $63.02. The impact to a portfolio due to this sale was -0.06%. Baker Bros. Advisors Lp still held 357,083 shares as of .

Baker Bros. Advisors Lp reduced to a holding in Adaptive Biotechnologies Corp by 33.32%. The sale prices were between $16.96 and $34.16, with an estimated average price of $27.98. The stock is now traded at around $38.92. The impact to a portfolio due to this sale was -0.06%. Baker Bros. Advisors Lp still held 743,734 shares as of .

Baker Bros. Advisors Lp reduced to a holding in Abeona Therapeutics Inc by 30.48%. The sale prices were between $1.45 and $4.08, with an estimated average price of $2.69. The stock is now traded at around $3.24. The impact to a portfolio due to this sale was -0.01%. Baker Bros. Advisors Lp still held 1,590,686 shares as of .

Baker Bros. Advisors Lp reduced to a holding in Catalyst Pharmaceuticals Inc by 20.95%. The sale prices were between $2.61 and $5.21, with an estimated average price of $4.11. The stock is now traded at around $4.31. The impact to a portfolio due to this sale was -0.01%. Baker Bros. Advisors Lp still held 1,060,714 shares as of .

Baker Bros. Advisors Lp reduced to a holding in G1 Therapeutics Inc by 30.82%. The sale prices were between $9.07 and $26.43, with an estimated average price of $18.9. The stock is now traded at around $18.13. The impact to a portfolio due to this sale was -0.01%. Baker Bros. Advisors Lp still held 88,026 shares as of .